Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2017 May 27

PMID 28546712

Citations 5

Authors

Ananthakrishnan Sivaraman

Kulthe Ramesh Seetharam Bhat

Affiliations

Soon will be listed here.

Abstract

Screening of prostatic cancer is a matter of debate among uro-oncologist. With many new screening modalities like prostatic health index (PHI), 4K testing the role of screening has increased as one is able to stratify patients with serum prostate specific antigen level in a grey zone of 4-10 ng/ml and normal digital rectal examination into various risk groups, thus avoiding unnecessary biopsy which was the pitfalls of routine screening practice. PHI is better at predicting malignancy while 4K is better at predicting high-grade disease. This in combination with multiparametric MRI especially with prostate imaging reporting and data system score has made screening less difficult and more meaningful for a practising uro-oncologist.

Citing Articles

Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.

Bauso L, La Fauci V, Munao S, Bonfiglio D, Armeli A, Maimone N Int J Mol Sci. 2024; 25(13).

PMID: 39000371 PMC: 11242495. DOI: 10.3390/ijms25137264.

New Therapeutic Perspectives in Prostate Cancer: Patient-Derived Organoids and Patient-Derived Xenograft Models in Precision Medicine.

Rago V, Perri A, Di Agostino S Biomedicines. 2023; 11(10).

PMID: 37893116 PMC: 10604340. DOI: 10.3390/biomedicines11102743.

The Impact of Metabolic Syndrome and Type 2 Diabetes on Prostate Cancer.

Sousa A, Costa R, Alves M, Soares R, Baylina P, Fernandes R Front Cell Dev Biol. 2022; 10:843458.

PMID: 35399507 PMC: 8992047. DOI: 10.3389/fcell.2022.843458.

Magnetic resonance imaging-guided prostate biopsy-A review of literature.

Bhat K, Samavedi S, Moschovas M, Onol F, Roof S, Rogers T Asian J Urol. 2021; 8(1):105-116.

PMID: 33569277 PMC: 7859420. DOI: 10.1016/j.ajur.2020.07.001.

Aptamer-Functionalized Natural Protein-Based Polymers as Innovative Biomaterials.

Girotti A, Escalera-Anzola S, Alonso-Sampedro I, Gonzalez-Valdivieso J, Javier Arias F Pharmaceutics. 2020; 12(11).

PMID: 33228250 PMC: 7699523. DOI: 10.3390/pharmaceutics12111115.

References

Woodrum D, Brawer M, Partin A, Catalona W, Southwick P . Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1997; 159(1):5-12. DOI: 10.1016/s0022-5347(01)63996-x. View

Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S . Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013; 111(6):928-33. DOI: 10.1111/j.1464-410X.2012.11683.x. View

De Coninck V, Braeckman J, Michielsen D . Prostate HistoScanning: a screening tool for prostate cancer?. Int J Urol. 2013; 20(12):1184-90. DOI: 10.1111/iju.12148. View

Turkbey B, Choyke P . PIRADS 2.0: what is new?. Diagn Interv Radiol. 2015; 21(5):382-4. PMC: 4557320. DOI: 10.5152/dir.2015.15099. View

DAmico A, Chen M, Roehl K, Catalona W . Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351(2):125-35. DOI: 10.1056/NEJMoa032975. View

Barentsz J, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G . ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4):746-57. PMC: 3297750. DOI: 10.1007/s00330-011-2377-y. View

Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona F . PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?. Int Braz J Urol. 2012; 38(4):489-95. DOI: 10.1590/s1677-55382012000400008. View

Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G . Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One. 2013; 8(7):e67687. PMC: 3701535. DOI: 10.1371/journal.pone.0067687. View

Koutros S, Meyer T, Fox S, Issaq H, Veenstra T, Huang W . Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 2013; 34(10):2281-5. PMC: 3786375. DOI: 10.1093/carcin/bgt176. View

10.

Carter H, Walsh P, Landis P, Epstein J . Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167(3):1231-4. View

11.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

12.

Benson M, Whang I, Pantuck A, Ring K, Kaplan S, Olsson C . Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147(3 Pt 2):815-6. DOI: 10.1016/s0022-5347(17)37393-7. View

13.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

14.

Culig Z, Santer F . Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. Steroids. 2013; 78(9):851-9. DOI: 10.1016/j.steroids.2013.04.012. View

15.

McCormack R, Rittenhouse H, Finlay J, Sokoloff R, Wang T, Wolfert R . Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995; 45(5):729-44. DOI: 10.1016/s0090-4295(99)80076-4. View

16.

Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Amirkhan A . Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003; 170(6 Pt 1):2181-5. DOI: 10.1097/01.ju.0000095460.12999.43. View

17.

Zhang Z, Zhang X, Newman K, Liu X, Seth P . MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol Cancer Ther. 2012; 11(11):2410-8. DOI: 10.1158/1535-7163.MCT-12-0157. View

18.

Leyten G, Hessels D, Smit F, Jannink S, de Jong H, Melchers W . Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015; 21(13):3061-70. DOI: 10.1158/1078-0432.CCR-14-3334. View

19.

Loeb S, Sokoll L, Broyles D, Bangma C, van Schaik R, Klee G . Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol. 2012; 189(5):1702-6. PMC: 4273580. DOI: 10.1016/j.juro.2012.11.149. View

20.

Junker D, De Zordo T, Quentin M, Ladurner M, Bektic J, Horniger W . Real-time elastography of the prostate. Biomed Res Int. 2014; 2014:180804. PMC: 4054974. DOI: 10.1155/2014/180804. View